Page last updated: 2024-10-19

niacin and Hypertriglyceridemia

niacin has been researched along with Hypertriglyceridemia in 85 studies

Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.

Hypertriglyceridemia: A condition of elevated levels of TRIGLYCERIDES in the blood.

Research Excerpts

ExcerptRelevanceReference
"Atorvastatin may allow patients with combined hyperlipidemia to be treated with monotherapy and offers an efficacious and well-tolerated alternative to niacin for the treatment of patients with isolated hypertriglyceridemia."9.08A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group. ( Black, DM; Kafonek, S; Koren, M; McCormick, LS; McKenney, JM; Weiss, S, 1998)
"Niacin was more effective at lowering LDL-C, Lp (a), and hs-CRP."6.75Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg. ( Cho, SY; Chung, N; Jang, Y; Kang, SM; Kim, JY; Lee, SH; Park, S; Shim, WH; Wi, J, 2010)
"Hypertriglyceridemia affects approximately 33% of the US population."6.52Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. ( Ito, MK, 2015)
"Patients with hypertriglyceridemia have been shown to respond well to dietary control and to the use of lipid lowering drugs such as 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG CoA) reductase inhibitors (known as statins), fibrates and nicotinic acids."6.41Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin. ( Breuer, HW, 2001)
"We compared the effects of aerobic exercise and 6 wk of extended-release niacin on postprandial triglycerides in men with the metabolic syndrome."5.13Postprandial triglyceride responses to aerobic exercise and extended-release niacin. ( Grandjean, PW; Mahurin, AJ; Mestek, ML; Moncada-Jimenez, J; Plaisance, EP; Taylor, JK, 2008)
"Atorvastatin may allow patients with combined hyperlipidemia to be treated with monotherapy and offers an efficacious and well-tolerated alternative to niacin for the treatment of patients with isolated hypertriglyceridemia."5.08A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group. ( Black, DM; Kafonek, S; Koren, M; McCormick, LS; McKenney, JM; Weiss, S, 1998)
" Sixty-five patients with low high-density lipoprotein (HDL) levels and hypertriglyceridemia were randomized to 1 of 3 treatment arms: pravastatin/niacin, pravastatin/magnesium, or pravastatin/placebo."5.08Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. ( Harris, WS; Nelson, J; O'Keefe, JH; Windsor, SL, 1995)
"MEDLINE was searched for articles published from 1990 through 2006 using the terms hypertriglyceridemia, dyslipidemia, and coronary heart disease, with subheadings for risk, statins, niacin, fibrates, thiazolidinediones, and omega-3 fatty acids."4.84Hypertriglyceridemia and cardiovascular risk reduction. ( Jacobson, TA; Miller, M; Schaefer, EJ, 2007)
"2%) of participants used 1 of 3 prescription medications indicated to treat hypertriglyceridemia (ie, fenofibrate, gemfibrozil, or niacin); this percentage was 2."3.75Hypertriglyceridemia and its pharmacologic treatment among US adults. ( Ford, ES; Li, C; Mokdad, AH; Pearson, WS; Zhao, G, 2009)
"Niacin has been reported to lower apoB and Lp(a) and to raise apoA-1."2.78Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). ( Albers, JJ; Kashyap, ML; Kwiterovich, PO; Marcovina, SM; O'Brien, KD; Robinson, JG; Slee, A; Xu, P, 2013)
" Further study is warranted to determine whether mealtime dosing would augment the clinical efficacy of extended-release niacin therapy."2.77Extended-release niacin acutely suppresses postprandial triglyceridemia. ( Dunbar, RL; Gadi, R; Goel, H; Hampson, J; Lilly, S; Mucksavage, ML; Nathanson, GA; Qamar, A; Rader, DJ; Usman, MH, 2012)
"Niacin was more effective at lowering LDL-C, Lp (a), and hs-CRP."2.75Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg. ( Cho, SY; Chung, N; Jang, Y; Kang, SM; Kim, JY; Lee, SH; Park, S; Shim, WH; Wi, J, 2010)
"Large randomized clinical trials are currently under way to test the cardiovascular benefits of omega-3 fatty acids at a pharmacologic dosage (4 g/day)."2.61New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease. ( Preston Mason, R, 2019)
"Therefore, hypertriglyceridemia is recognized as a therapeutic target in the treatment of endothelial dysfunction."2.61Triglycerides and endothelial function: molecular biology to clinical perspective. ( Higashi, Y; Kajikawa, M, 2019)
"Hypertriglyceridemia is often a polygenic condition that can be affected by numerous interventions."2.58Hypertriglyceridemia: A review of the evidence. ( Elkins, C; Friedrich, D, 2018)
"Hypertriglyceridemia is increasingly identified in children and adolescents, owing to improved screening and higher prevalence of childhood obesity."2.55Approach to Hypertriglyceridemia in the Pediatric Population. ( Ashraf, AP; Sunil, B; Valaiyapathi, B, 2017)
"Hypertriglyceridemia affects approximately 33% of the US population."2.52Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. ( Ito, MK, 2015)
"Hypertriglyceridemia is an important marker of increased levels of highly atherogenic remnant-like particles."2.52Treatment of hypertriglyceridemia: a review of current options. ( Češka, R; Vrablík, M, 2015)
"Hypertriglyceridemia is associated with an atherogenic metabolic profile and in most studies with increased cardiovascular disease risk."2.50Recommendations for severe hypertriglyceridemia treatment, are there new strategies? ( Elisaf, MS; Filippatos, TD, 2014)
"Hyperlipidemia is common in dogs, and can be either primary or secondary to other diseases."2.46Lipid metabolism and hyperlipidemia in dogs. ( Steiner, JM; Xenoulis, PG, 2010)
"The lipid profile of type 2 diabetes mellitus is characterized by increased triglycerides (TGs), decreased high-density lipoprotein cholesterol (HDL-C), increased very low density lipoproteins (VLDLs), and small, dense low-density lipoprotein particles, the combination of which is highly atherogenic."2.45Managing diabetic dyslipidemia: beyond statin therapy. ( Gadi, R; Neeli, H; Rader, DJ, 2009)
"Furthermore, severe hypertriglyceridemia is associated with an increased risk of acute pancreatitis, irrespective of its effect on risk of cardiovascular disease."2.44Hypertriglyceridemia: its etiology, effects and treatment. ( Al-Shali, KZ; Hegele, RA; Yuan, G, 2007)
"Hypertriglyceridemia is associated with an increased risk of cardiovascular events and acute pancreatitis."2.44Management of hypertriglyceridemia. ( Lanier, JB; Oh, RC, 2007)
"Fifth, combined hyperlipidemia is the most common lipid disorder, has the strongest risk for CVD, and combines elevated LDL, hypertriglyceridemia, and low HDL."2.44Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk. ( Atkinson, B; Dowdy, A; Knopp, RH; Paramsothy, P, 2008)
"Hypertriglyceridemia is a commonly encountered problem in primary care practice."2.44Bridging the gap in treatment options for patients with hypertriglyceridemia. ( Hays, R; Underberg, JA, 2007)
"Dyslipidemia is characterized by increased triglyceride-rich lipoproteins; low high-density lipoprotein cholesterol; small, dense low-density lipoprotein particles; increased postprandial lipemia; and abnormal apolipoprotein A1 and B metabolism."2.42Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome. ( Cottrell, DA; Falko, JM; Marshall, BJ, 2003)
"Patients with hypertriglyceridemia have been shown to respond well to dietary control and to the use of lipid lowering drugs such as 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG CoA) reductase inhibitors (known as statins), fibrates and nicotinic acids."2.41Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin. ( Breuer, HW, 2001)
"Hypertriglyceridemia is commonly embedded in the context of a metabolic syndrome that includes central obesity, insulin resistance, low levels of HDL cholesterol, and often hypertension."2.41A risk factor for atherosclerosis: triglyceride-rich lipoproteins. ( Kane, JP; Malloy, MJ, 2001)
"Hypertriglyceridemia has been recently recognized as a vascular risk factor, based on both clinical and experimental findings."2.38Pharmacological control of hypertriglyceridemia. ( Franceschini, G; Paoletti, R, 1993)
"Hypertriglyceridemia is a theoretical risk factor for CHD because of the increased production of atherogenic chylomicron and VLDL remnants, the inverse relationship present between serum triglyceride and HDL, the possible resultant increase in LDL attributable to remnant-reduced hepatic LDL-receptors as well as the formation of more dense and, therefore, more atherogenic LDL, and to the interaction between serum triglyceride and the fibrinolytic/coagulation system."2.38The triglyceride connection in atherosclerosis. ( Geurian, K; Pinson, JB; Weart, CW, 1992)
" Our aim was to find a rational NiAc dosing regimen that preserves FFA lowering, sufficient to reverse nonadipose tissue lipid accumulation and improve metabolic control, in obese Zucker rats."1.46Nicotinic acid timed to feeding reverses tissue lipid accumulation and improves glucose control in obese Zucker rats[S]. ( Baccega, T; Gabrielsson, J; Kroon, T; Oakes, ND; Olsén, A, 2017)
"The conventional methods of treatment of severe hypertriglyceridemia are dietary restriction and lipid lowering medications, mainly fibric acid derivatives."1.37Rapid reduction of severely elevated serum triglycerides with insulin infusion, gemfibrozil and niacin. ( Pathak, RD; Pathak, SR; Poonuru, S; Vats, HS, 2011)
"Dyslipidemia is frequently found in association with obesity."1.37Obesity and dyslipidemia. ( Repas, T, 2011)
"Niacin and fibrates have been shown in clinical trials to be effective as adjunctive therapy for these lipid abnormalities."1.35Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol. ( Laitinen, D; Sullivan, JM; Toth, PP; Zarotsky, V, 2009)

Research

Studies (85)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's20 (23.53)18.2507
2000's34 (40.00)29.6817
2010's30 (35.29)24.3611
2020's1 (1.18)2.80

Authors

AuthorsStudies
Oh, RC2
Trivette, ET1
Westerfield, KL1
Valaiyapathi, B1
Sunil, B1
Ashraf, AP1
Elkins, C1
Friedrich, D1
Preston Mason, R1
Kajikawa, M1
Higashi, Y1
Filippatos, TD1
Elisaf, MS1
Albers, JJ1
Slee, A1
O'Brien, KD1
Robinson, JG1
Kashyap, ML1
Kwiterovich, PO1
Xu, P1
Marcovina, SM1
Aye, MM1
Kilpatrick, ES1
Afolabi, P1
Wootton, SA1
Rigby, AS1
Coady, AM1
Sandeman, DD1
Atkin, SL1
Croyal, M1
Ouguerram, K1
Passard, M1
Ferchaud-Roucher, V1
Chétiveaux, M1
Billon-Crossouard, S1
de Gouville, AC1
Lambert, G1
Krempf, M1
Nobécourt, E1
Ito, MK1
Vrablík, M1
Češka, R1
Grammer, T1
Kleber, M1
Silbernagel, G1
Scharnagl, H1
März, W1
Handelsman, Y1
Shapiro, MD1
Kroon, T1
Baccega, T1
Olsén, A1
Gabrielsson, J1
Oakes, ND1
Nichols, GA1
Reynolds, K1
Olufade, T1
Kimes, TM1
O'Keeffe-Rosetti, M1
Sapp, DS1
Anzalone, D1
Fortmann, SP1
Codario, RA1
Plaisance, EP2
Mestek, ML1
Mahurin, AJ2
Taylor, JK1
Moncada-Jimenez, J1
Grandjean, PW2
Underberg, JA1
Hays, R1
Gandotra, P1
Miller, M3
Xenoulis, PG1
Steiner, JM1
Neeli, H1
Gadi, R2
Rader, DJ4
Ford, ES1
Li, C1
Zhao, G1
Pearson, WS1
Mokdad, AH1
Alagona, P1
Toth, PP1
Zarotsky, V1
Sullivan, JM1
Laitinen, D1
Szafarz, M1
Lomnicka, M1
Sternak, M1
Chlopicki, S1
Szymura-Oleksiak, J1
Jialal, I1
Amess, W1
Kaur, M1
Souza, SA1
Chow, DC1
Walsh, EJ1
Ford, S1
Shikuma, C1
Poonuru, S1
Pathak, SR1
Vats, HS1
Pathak, RD1
Wi, J1
Kim, JY1
Park, S1
Kang, SM1
Jang, Y1
Chung, N1
Shim, WH1
Cho, SY1
Lee, SH1
Johansen, CT1
Kathiresan, S1
Hegele, RA2
Klose, G1
Custodis, F1
Laufs, U1
Repas, T1
Sharpe, P1
Hu, M1
Chu, WC1
Yamashita, S1
Yeung, DK1
Shi, L1
Wang, D1
Masuda, D1
Yang, Y1
Tomlinson, B1
Usman, MH1
Qamar, A1
Lilly, S1
Goel, H1
Hampson, J1
Mucksavage, ML1
Nathanson, GA1
Dunbar, RL2
Berglund, L1
Brunzell, J1
Sacks, FM1
Wooten, JS1
Nambi, P1
Gillard, BK1
Pownall, HJ1
Coraza, I1
Scott, LW1
Nambi, V1
Ballantyne, CM1
Balasubramanyam, A1
Fung, MA1
Frohlich, JJ1
Cottrell, DA1
Marshall, BJ1
Falko, JM1
Gouni-Berthold, I1
Krone, W1
Pins, JJ1
Keenan, JM1
Langenberg, P1
Havas, S1
Yuan, G1
Al-Shali, KZ1
Lanier, JB1
Jacobson, TA1
Schaefer, EJ1
Brunzell, JD1
Nagao, M1
Oikawa, S1
Yavasoglu, I1
Kadikoylu, G1
Bolaman, Z1
Röggla, G1
Fasan, M1
Kapiotis, S1
Holub, BJ1
Oh, R1
Raghavan, VA1
Scanu, AM1
Bamba, R1
Knopp, RH1
Paramsothy, P1
Atkinson, B1
Dowdy, A1
O'Keefe, JH2
Harris, WS2
Nelson, J1
Windsor, SL1
Bays, H1
Lansing, AM1
van der Wel, AM1
Castro Cabezas, M1
de Bruin, TW1
Erkelens, DW1
Franceschini, G2
Paoletti, R2
Lavie, CJ3
Saloranta, C1
Groop, L1
Johansson, JO1
Egberg, N1
Asplund-Carlson, A1
Carlson, LA2
Grundy, SM2
Vega, GL1
McKenney, JM1
McCormick, LS1
Weiss, S1
Koren, M1
Kafonek, S1
Black, DM1
Gotto, AM1
Scheen, AJ1
Ginsberg, HN1
Coughlan, BJ1
Sorrentino, MJ1
Milani, RV2
Breuer, HW1
Szapary, PO1
Wierzbicki, AS1
Reynolds, TM1
Crook, MA1
Malloy, MJ1
Kane, JP1
Wahlberg, G1
Walldius, G1
Efendic, S1
Geurian, K1
Pinson, JB1
Weart, CW1
Mailander, L1
Capurso, A1
Tornvall, P1
Hamsten, A1
Johansson, J1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Study of the Effect of Eicosapentaenoic Acid (EPA) on Markers of Atherothrombosis in Patients With Type-2 Diabetes[NCT06129526]Phase 4450 participants (Anticipated)Interventional2023-12-31Not yet recruiting
AIM HIGH: Niacin Plus Statin to Prevent Vascular Events[NCT00120289]Phase 33,414 participants (Actual)Interventional2005-09-30Terminated (stopped due to AIM-HIGH was stopped on the recommendation of the DSMB because of lack of efficacy of niacin in preventing primary outcome events.)
To Determine if the Cardiovascular Risk Indices Including Postprandial Hypertriglyceridaemia Are Modified Favourably by Nicotinic Acid (Niacin) in Patients With Polycystic Ovary Syndrome ( PCOS)[NCT01118598]Phase 434 participants (Actual)Interventional2010-06-30Completed
Influences of Physical Activity in the Profile of Trans Fatty Acids in the Serum of Individuals With Body Weight Changes[NCT03170973]66 participants (Anticipated)Interventional2017-05-31Recruiting
Time to Complications Occurs in Diabetes. Risk Factors Determine When Diabetes Complications Occur[NCT00969956]17 participants (Actual)Observational2012-04-30Terminated (stopped due to Local regulations)
Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy[NCT00246376]221 participants (Actual)Interventional2004-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Cardiovascular Mortality

(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination), for an average of 36 months follow-up, maximum 66 months.

Interventionparticipants (Number)
ERN + Simvastatin45
Placebo + Simvastatin38

Composite End Point of CHD Death, Nonfatal MI, Ischemic Stroke, Hospitalization for Non-ST Segment Elevation Acute Coronary Syndrome (ACS), or Symptom-driven Coronary or Cerebral Revascularization

(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination) for an average of 36 months follow-up, maximum 66 months.

Interventionparticipants (Number)
ERN + Simvastatin282
Placebo + Simvastatin274

Composite Endpoint of CHD Death, Non-fatal MI, High-risk ACS or Ischemic Stroke

(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination) for an average of 36 months follow-up, maximum 66 months

Interventionparticipants (Number)
ERN + Simvastatin171
Placebo + Simvastatin158

Composite Endpoint of CHD Death, Non-fatal MI, or Ischemic Stroke

(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination) for an average of 36 months follow-up, maximum 66 months

Interventionparticipants (Number)
ERN + Simvastatin156
Placebo + Simvastatin138

HDL-C

HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dl (Mean)
Group 1 - Usual Care37.1
Group 2 - Diet/Exercise Only38.7
Group 3 - Diet/Exercise + Fenofibrate40.7
Group 4 - Diet/Exercise + Niacin41.8
Group 5 - Diet/Exercise + Fenofibrate + Niacin44.8

Non-HDL-C

non-HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dl (Mean)
Group 1 - Usual Care162.2
Group 2 - Diet/Exercise Only165.4
Group 3 - Diet/Exercise + Fenofibrate145.8
Group 4 - Diet/Exercise + Niacin154
Group 5 - Diet/Exercise + Fenofibrate + Niacin137.1

Total Cholesterol

Total cholesterol (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dL (Mean)
Group 1 - Usual Care195.6
Group 2 - Diet/Exercise Only200.1
Group 3 - Diet/Exercise + Fenofibrate184
Group 4 - Diet/Exercise + Niacin190.8
Group 5 - Diet/Exercise + Fenofibrate + Niacin178.4

Total Cholesterol : HDL-C Ratio

Total cholesterol : HDL-C ratio: Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionratio (Mean)
Group 1 - Usual Care5.2
Group 2 - Diet/Exercise Only5.1
Group 3 - Diet/Exercise + Fenofibrate4.5
Group 4 - Diet/Exercise + Niacin4.6
Group 5 - Diet/Exercise + Fenofibrate + Niacin4

Triglycerides

Triglycerides (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dL (Mean)
Group 1 - Usual Care199
Group 2 - Diet/Exercise Only216.9
Group 3 - Diet/Exercise + Fenofibrate155.1
Group 4 - Diet/Exercise + Niacin177.6
Group 5 - Diet/Exercise + Fenofibrate + Niacin135.6

Body Composition

"Body cell mass (kg)~Fat mass (kg)" (NCT00246376)
Timeframe: Measured at 24 weeks

,,,,
Interventionkg (Mean)
Body cell massFat mass
Group 1 - Usual Care59.636.8
Group 2 - Diet/Exercise67.337.5
Group 3 - Diet/Exercise + Fenofibrate66.635.8
Group 4 - Diet/Exercise + Niacin67.137.7
Group 5 - Diet/Exercise + Fenofibrate + Niacin68.236.2

Insulin Sensitivity

Adiponectin (micrograms/ml) (NCT00246376)
Timeframe: Measured at 24 weeks

,,,,
Interventionmicrograms/ml (Mean)
Fasting insulinHOMA-IRInsulin sensitvity indexAdiponectin
Group 1 - Usual Care8.71.923.547.12
Group 2 - Diet/Exercise Only6.71.384.956.04
Group 3 - Diet/Exercise + Fenofibrate9.52.023.815.24
Group 4 - Diet/Exercise + Niacin11.92.762.8811.01
Group 5 - Diet/Exercise + Fenofibrate + Niacin10.32.382.3810.34

Reviews

44 reviews available for niacin and Hypertriglyceridemia

ArticleYear
Management of Hypertriglyceridemia: Common Questions and Answers.
    American family physician, 2020, 09-15, Volume: 102, Issue:6

    Topics: Family Practice; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyper

2020
Approach to Hypertriglyceridemia in the Pediatric Population.
    Pediatrics in review, 2017, Volume: 38, Issue:9

    Topics: Child; Fatty Acids, Omega-3; Fibric Acids; Healthy Lifestyle; Humans; Hydroxymethylglutaryl-CoA Redu

2017
Hypertriglyceridemia: A review of the evidence.
    The Nurse practitioner, 2018, Volume: 43, Issue:10

    Topics: Diet; Exercise; Fatty Acids, Omega-3; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhi

2018
New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.
    Current atherosclerosis reports, 2019, 01-12, Volume: 21, Issue:1

    Topics: Atherosclerosis; Cell Membrane; Cholesterol, LDL; Coronary Thrombosis; Docosahexaenoic Acids; Eicosa

2019
Triglycerides and endothelial function: molecular biology to clinical perspective.
    Current opinion in lipidology, 2019, Volume: 30, Issue:5

    Topics: Cardiovascular Diseases; Endothelial Cells; Fatty Acids, Omega-3; Fibric Acids; Humans; Hydroxymethy

2019
Recommendations for severe hypertriglyceridemia treatment, are there new strategies?
    Current vascular pharmacology, 2014, Volume: 12, Issue:4

    Topics: Algorithms; Blood Component Removal; Cardiovascular Diseases; Diet, Fat-Restricted; Fatty Acids, Ome

2014
Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.
    Atherosclerosis, 2015, Volume: 242, Issue:2

    Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, Omega-3; Fibric Acids; Hum

2015
Treatment of hypertriglyceridemia: a review of current options.
    Physiological research, 2015, Volume: 64, Issue:Suppl 3

    Topics: Animals; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyce

2015
TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2017, Volume: 23, Issue:1

    Topics: Atherosclerosis; Cardiovascular Diseases; Fatty Acids, Omega-3; Fenofibrate; Fibric Acids; Humans; H

2017
Bridging the gap in treatment options for patients with hypertriglyceridemia.
    The Journal of family practice, 2007, Volume: 56, Issue:12 Suppl N

    Topics: Adult; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Comorbidity; Drug Monitoring; Drug

2007
The role of triglycerides in cardiovascular risk.
    Current cardiology reports, 2008, Volume: 10, Issue:6

    Topics: Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Humans; Hypertriglyceridemia;

2008
Lipid metabolism and hyperlipidemia in dogs.
    Veterinary journal (London, England : 1997), 2010, Volume: 183, Issue:1

    Topics: Animals; Diet, Reducing; Dog Diseases; Dogs; Fatty Acids, Omega-3; Hyperlipidemias; Hypertriglycerid

2010
Managing diabetic dyslipidemia: beyond statin therapy.
    Current diabetes reports, 2009, Volume: 9, Issue:1

    Topics: Cholesterol, HDL; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Angi

2009
Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    The American journal of managed care, 2009, Volume: 15, Issue:3 Suppl

    Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Fenofibrate; Humans; Hydroxymethylgluta

2009
Independent and combined effects of aerobic exercise and pharmacological strategies on serum triglyceride concentrations: a qualitative review.
    The Physician and sportsmedicine, 2009, Volume: 37, Issue:1

    Topics: Combined Modality Therapy; Exercise; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reducta

2009
Management of hypertriglyceridemia in the diabetic patient.
    Current diabetes reports, 2010, Volume: 10, Issue:4

    Topics: Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; H

2010
Genetic determinants of plasma triglycerides.
    Journal of lipid research, 2011, Volume: 52, Issue:2

    Topics: Adaptor Proteins, Signal Transducing; Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Angio

2011
[Hypertricglyceridemia: prognostic impact and treatment options].
    Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:30

    Topics: Adult; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diet, R

2011
Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome.
    Current opinion in cardiology, 2003, Volume: 18, Issue:4

    Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopat

2003
Demystifying triglycerides: a practical approach for the clinician.
    Cleveland Clinic journal of medicine, 2005, Volume: 72, Issue:8

    Topics: Arteriosclerosis; Clofibric Acid; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors;

2005
Hypertriglyceridemia-why, when and how should it be treated?
    Zeitschrift fur Kardiologie, 2005, Volume: 94, Issue:11

    Topics: Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Comorbidity; Evidence-Based Medic

2005
Dietary and nutraceutical options for managing the hypertriglyceridemic patient.
    Progress in cardiovascular nursing, 2006,Spring, Volume: 21, Issue:2

    Topics: Dietary Carbohydrates; Energy Intake; Evidence-Based Medicine; Exercise; Fasting; Fish Oils; Humans;

2006
Hypertriglyceridemia: its etiology, effects and treatment.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2007, Apr-10, Volume: 176, Issue:8

    Topics: Clofibric Acid; Coronary Artery Disease; Diet; Exercise; Humans; Hydroxymethylglutaryl-CoA Reductase

2007
Management of hypertriglyceridemia.
    American family physician, 2007, May-01, Volume: 75, Issue:9

    Topics: Clofibric Acid; Diet; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrigly

2007
Hypertriglyceridemia and cardiovascular risk reduction.
    Clinical therapeutics, 2007, Volume: 29, Issue:5

    Topics: Atherosclerosis; Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Fatty Acids, Omega-3; Hu

2007
Clinical practice. Hypertriglyceridemia.
    The New England journal of medicine, 2007, Sep-06, Volume: 357, Issue:10

    Topics: Adult; Aged; Apolipoproteins B; Cholesterol; Clofibric Acid; Combined Modality Therapy; Diet Therapy

2007
[Intervention for hypertriglyceridemia].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Jul-28, Volume: 65 Suppl 7

    Topics: Aged; Bezafibrate; Clofibric Acid; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Female; Humans;

2007
Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations.
    The American journal of cardiology, 2008, Apr-17, Volume: 101, Issue:8A

    Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Humans; Hypertriglyceri

2008
Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk.
    The American journal of cardiology, 2008, Apr-17, Volume: 101, Issue:8A

    Topics: Anticholesteremic Agents; Apolipoprotein A-I; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol

2008
[Triglycerides and atherosclerosis; treatment of hypertriglyceridemia].
    Nederlands tijdschrift voor geneeskunde, 1994, Feb-26, Volume: 138, Issue:9

    Topics: Arteriosclerosis; Chylomicrons; Diet, Reducing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibito

1994
Pharmacological control of hypertriglyceridemia.
    Cardiovascular drugs and therapy, 1993, Volume: 7, Issue:3

    Topics: Body Weight; Cardiovascular Diseases; Clofibrate; Exercise; Fatty Acids, Omega-3; Humans; Hypertrigl

1993
Drugs controlling triglyceride metabolism.
    Medicinal research reviews, 1993, Volume: 13, Issue:2

    Topics: Anticholesteremic Agents; Arteriosclerosis; Fatty Acids, Omega-3; Humans; Hypertriglyceridemia; Metf

1993
Interactions between glucose and FFA metabolism in man.
    Diabetes/metabolism reviews, 1996, Volume: 12, Issue:1

    Topics: Animals; Biological Transport; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose; Human

1996
Nicotinic acid--the underused ally in the fight against coronary disease.
    Journal of cardiovascular risk, 1997, Volume: 4, Issue:3

    Topics: Clinical Trials as Topic; Coronary Disease; Drug Utilization; Humans; Hypertriglyceridemia; Niacin;

1997
Consensus statement: Role of therapy with "statins" in patients with hypertriglyceridemia.
    The American journal of cardiology, 1998, Feb-26, Volume: 81, Issue:4A

    Topics: Cholesterol, HDL; Cholesterol, VLDL; Clinical Trials as Topic; Consensus Development Conferences as

1998
Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men.
    The American journal of cardiology, 1998, Feb-26, Volume: 81, Issue:4A

    Topics: Apolipoproteins B; Cholesterol, LDL; Cholesterol, VLDL; Gemfibrozil; Humans; Hydroxymethylglutaryl-C

1998
Triglyceride as a risk factor for coronary artery disease.
    The American journal of cardiology, 1998, Nov-05, Volume: 82, Issue:9A

    Topics: Biomarkers; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus,

1998
Identification and treatment of hypertriglyceridemia as a risk factor for coronary heart disease.
    Current cardiology reports, 1999, Volume: 1, Issue:3

    Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Humans; Hypertriglyceridemia; Hypolipi

1999
Does hypertriglyceridemia increase risk for CAD? Growing evidence suggests it plays a role.
    Postgraduate medicine, 2000, Volume: 108, Issue:7

    Topics: Coronary Disease; Diabetes Complications; Evidence-Based Medicine; Humans; Hypertriglyceridemia; Hyp

2000
Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Current medical research and opinion, 2001, Volume: 17, Issue:1

    Topics: Atorvastatin; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Heptanoic Acids; Humans; Hyd

2001
Pharmacological management of high triglycerides and low high-density lipoprotein cholesterol.
    Current opinion in pharmacology, 2001, Volume: 1, Issue:2

    Topics: Acids, Acyclic; Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Epidemiologic Studies;

2001
A risk factor for atherosclerosis: triglyceride-rich lipoproteins.
    Advances in internal medicine, 2001, Volume: 47

    Topics: Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxym

2001
The triglyceride connection in atherosclerosis.
    The Annals of pharmacotherapy, 1992, Volume: 26, Issue:9

    Topics: Alcohol Drinking; Arteriosclerosis; Coronary Disease; Diabetes Complications; Diet; Exercise; Humans

1992
Drugs affecting triglycerides.
    Cardiology, 1991, Volume: 78, Issue:3

    Topics: Benzhydryl Compounds; Clofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Niacin

1991

Trials

10 trials available for niacin and Hypertriglyceridemia

ArticleYear
Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).
    Journal of the American College of Cardiology, 2013, Oct-22, Volume: 62, Issue:17

    Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL;

2013
Postprandial effects of long-term niacin/laropiprant use on glucose and lipid metabolism and on cardiovascular risk in patients with polycystic ovary syndrome.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:6

    Topics: Adult; Blood Glucose; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Meth

2014
Effects of Extended-Release Nicotinic Acid on Apolipoprotein (a) Kinetics in Hypertriglyceridemic Patients.
    Arteriosclerosis, thrombosis, and vascular biology, 2015, Volume: 35, Issue:9

    Topics: Apoprotein(a); Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Do

2015
Postprandial triglyceride responses to aerobic exercise and extended-release niacin.
    The American journal of clinical nutrition, 2008, Volume: 88, Issue:1

    Topics: Adult; Analysis of Variance; Area Under Curve; Combined Modality Therapy; Cross-Over Studies; Dietar

2008
Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg.
    Atherosclerosis, 2010, Volume: 213, Issue:1

    Topics: Adult; Aged; Apolipoprotein A-I; Apolipoproteins B; Cholesterol, HDL; Female; Fenofibrate; Fibric Ac

2010
Extended-release niacin acutely suppresses postprandial triglyceridemia.
    The American journal of medicine, 2012, Volume: 125, Issue:10

    Topics: Biomarkers; Black or African American; Cross-Over Studies; Delayed-Action Preparations; Double-Blind

2012
Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients.
    Medicine and science in sports and exercise, 2013, Volume: 45, Issue:6

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Antiretroviral Therapy, Highly Active;

2013
Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia.
    The American journal of cardiology, 1995, Sep-01, Volume: 76, Issue:7

    Topics: Adult; Apolipoprotein A-I; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combinatio

1995
Nicotinic acid treatment shifts the fibrinolytic balance favourably and decreases plasma fibrinogen in hypertriglyceridaemic men.
    Journal of cardiovascular risk, 1997, Volume: 4, Issue:3

    Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Blood Glucose; Drug Administration Schedule

1997
A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.
    The American journal of medicine, 1998, Volume: 104, Issue:2

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Humans; H

1998

Other Studies

31 other studies available for niacin and Hypertriglyceridemia

ArticleYear
Drugs for hypertriglyceridemia.
    The Medical letter on drugs and therapeutics, 2013, Mar-04, Volume: 55, Issue:1411

    Topics: Biomarkers; Cardiovascular Diseases; Drug Interactions; Fibric Acids; Fish Oils; Humans; Hydroxymeth

2013
[Residual risk: The roles of triglycerides and high density lipoproteins].
    Deutsche medizinische Wochenschrift (1946), 2016, Volume: 141, Issue:12

    Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Fibric Acids

2016
Nicotinic acid timed to feeding reverses tissue lipid accumulation and improves glucose control in obese Zucker rats[S].
    Journal of lipid research, 2017, Volume: 58, Issue:1

    Topics: Animals; Blood Glucose; Fasting; Fatty Acids; Glucose; Glucose Tolerance Test; Humans; Hypertriglyce

2017
Effect of Combination Cholesterol-Lowering Therapy and Triglyceride-Lowering Therapy on Medical Costs in Patients With Type 2 Diabetes Mellitus.
    The American journal of cardiology, 2017, Feb-01, Volume: 119, Issue:3

    Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Cost-Benefit Analysis; Diabetes Mellitus,

2017
Hypertriglyceridemia and cardiovascular disease management.
    Journal of the American Academy of Nurse Practitioners, 2007, Volume: 19, Issue:12 Suppl 2

    Topics: Adult; Cardiovascular Diseases; Clofibric Acid; Disease Management; Fatty Acids, Omega-3; Female; Hu

2007
Hypertriglyceridemia and its pharmacologic treatment among US adults.
    Archives of internal medicine, 2009, Mar-23, Volume: 169, Issue:6

    Topics: Adult; Female; Fenofibrate; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; M

2009
Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol.
    Current medical research and opinion, 2009, Volume: 25, Issue:6

    Topics: Adult; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Drug Combinations; Female; Humans;

2009
Simultaneous determination of nicotinic acid and its four metabolites in rat plasma using high performance liquid chromatography with tandem mass spectrometric detection (LC/MS/MS).
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2010, Apr-01, Volume: 878, Issue:11-12

    Topics: Animals; Calibration; Chromatography, High Pressure Liquid; Hypertriglyceridemia; Niacin; Rats; Repr

2010
Pilot study on the safety and tolerability of extended release niacin for HIV-infected patients with hypertriglyceridemia.
    Hawaii medical journal, 2010, Volume: 69, Issue:5

    Topics: Adult; Delayed-Action Preparations; Glucose; HIV Seropositivity; Humans; Hypertriglyceridemia; Liver

2010
Rapid reduction of severely elevated serum triglycerides with insulin infusion, gemfibrozil and niacin.
    Clinical medicine & research, 2011, Volume: 9, Issue:1

    Topics: Adult; Gemfibrozil; Humans; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin

2011
[Optimal lipid treatment: possibilities and current limitations].
    Der Internist, 2011, Volume: 52, Issue:3

    Topics: Anion Exchange Resins; Anticholesteremic Agents; Blood Component Removal; Cardiovascular Diseases; C

2011
Obesity and dyslipidemia.
    South Dakota medicine : the journal of the South Dakota State Medical Association, 2011, Volume: 64, Issue:7

    Topics: Anti-Obesity Agents; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Dyslipidemias; Humans; H

2011
Paradoxical decrease in serum high-density lipoprotein cholesterol with Tredaptive® (m/r nicotinic acid 1 g and laropiprant 20 mg).
    Annals of clinical biochemistry, 2011, Volume: 48, Issue:Pt 6

    Topics: Adult; Cholesterol, HDL; Drug Combinations; Drug Substitution; Fenofibrate; Humans; Hypertriglycerid

2011
Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients.
    Journal of lipid research, 2012, Volume: 53, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Asian People; Body Weight; Diacylglycerol O-Acy

2012
Patient information page from The Hormone Foundations. Patient guide to the assessment and treatment of hypertriglyceridemia (high triglycerides).
    The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:9

    Topics: Fatty Acids, Omega-3; Fibric Acids; Humans; Hypertriglyceridemia; Life Style; Niacin; Triglycerides

2012
Common problems in the management of hypertriglyceridemia.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2002, Nov-26, Volume: 167, Issue:11

    Topics: Adult; Anticholesteremic Agents; Diagnosis, Differential; Diet; Dietary Fiber; Exercise; Fatty Acids

2002
Niacin for high triglycerides.
    TreatmentUpdate, 2002, Volume: 14, Issue:8

    Topics: Antiretroviral Therapy, Highly Active; Diet; Exercise; Humans; Hypertriglyceridemia; Niacin

2002
Impact of lowering triglycerides on raising HDL-C in hypertriglyceridemic and non-hypertriglyceridemic subjects.
    International journal of cardiology, 2007, Jul-10, Volume: 119, Issue:2

    Topics: Alcohol Drinking; Body Mass Index; Cholesterol, HDL; Diet; Exercise; Female; Humans; Hypertriglyceri

2007
Treating hypertriglyceridemia.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2007, Sep-11, Volume: 177, Issue:6

    Topics: Adult; Clofibric Acid; Coronary Artery Disease; Diet; Exercise; Heparin; Humans; Hydroxymethylglutar

2007
Treating hypertriglyceridemia.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2007, Sep-11, Volume: 177, Issue:6

    Topics: Clofibric Acid; Coronary Artery Disease; Diet; Exercise; Humans; Hydroxymethylglutaryl-CoA Reductase

2007
Treating hypertriglyceridemia.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2007, Sep-11, Volume: 177, Issue:6

    Topics: Clofibric Acid; Coronary Artery Disease; Diet; Exercise; Fatty Acids, Omega-3; Humans; Hydroxymethyl

2007
Hypertriglyceridemia.
    The New England journal of medicine, 2008, Jan-17, Volume: 358, Issue:3

    Topics: Dietary Supplements; Fatty Acids, Omega-3; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Niaci

2008
First-line therapies for lowering triglyceride levels.
    American family physician, 2008, Feb-15, Volume: 77, Issue:4

    Topics: Clofibric Acid; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceride

2008
Fish oil (omega-3 fatty acids) in treatment of hypertriglyceridemia. A practical approach for the primary care physician.
    The Journal of the Kentucky Medical Association, 1994, Volume: 92, Issue:3

    Topics: Aged; Clofibrate; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Gemfibrozil; Humans; Hype

1994
Sustained-release niacin for low levels of high-density lipoprotein cholesterol.
    Mayo Clinic proceedings, 1993, Volume: 68, Issue:2

    Topics: Cholesterol, HDL; Delayed-Action Preparations; Humans; Hypertriglyceridemia; Niacin

1993
[Drug clinics. How I treat a patient with a low concentration of HDL cholesterol].
    Revue medicale de Liege, 1998, Volume: 53, Issue:12

    Topics: Cholesterol, HDL; Cholesterol, LDL; Exercise Therapy; Heart Diseases; Humans; Hypercholesterolemia;

1998
Niacin in patients with diabetes mellitus and coronary artery disease.
    The American journal of cardiology, 2001, May-01, Volume: 87, Issue:9

    Topics: Coronary Disease; Diabetes Complications; Humans; Hypertriglyceridemia; Niacin

2001
Usefulness of Orlistat in the treatment of severe hypertriglyceridemia.
    The American journal of cardiology, 2002, Jan-15, Volume: 89, Issue:2

    Topics: Adult; Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Dietary Fiber; Drug Therapy, Com

2002
Effects of nicotinic acid on glucose tolerance and glucose incorporation into adipose tissue in hypertriglyceridaemia.
    Scandinavian journal of clinical and laboratory investigation, 1992, Volume: 52, Issue:6

    Topics: Adipose Tissue; Adult; Aged; Blood Glucose; Fatty Acids, Nonesterified; Female; Glucose; Glucose Tol

1992
Marked benefit with sustained-release niacin therapy in patients with "isolated" very low levels of high-density lipoprotein cholesterol and coronary artery disease.
    The American journal of cardiology, 1992, Apr-15, Volume: 69, Issue:12

    Topics: Cholesterol, HDL; Coronary Disease; Delayed-Action Preparations; Humans; Hypertriglyceridemia; Male;

1992
Normalisation of the composition of very low density lipoprotein in hypertriglyceridemia by nicotinic acid.
    Atherosclerosis, 1990, Volume: 84, Issue:2-3

    Topics: Adult; Cholesterol; Cholesterol Esters; Cholesterol, HDL; Female; Humans; Hypertriglyceridemia; Lipo

1990